Kintor Completes Enrollment for GT20029 Phase I Study in US
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of enrollment for a Phase I...
HKG: 9939
Kintor’s Dual c-Myc/GSPT1 Degradation Therapy GT19715 Shows Promise in Pre-Clinical Studies
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has published positive results from a pre-clinical study of...
Kintor Pharma Completes GT20029 Phase I Study for Hair Loss and Acne
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of dosing all 92 subjects in...